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Abstract The association between methylenetetrahydrofo-
late reductase (MTHFR) gene polymorphisms and breast can-
cer risk in the Chinese population has been widely reported,
but results were inconsistent. In order to derive a more precise
estimation of the relationship, a meta-analysis was performed.
Eligible articles were identified through search of databases
including Medline, PubMed, Web of Science, Embase,
Chinese Biomedical Literature Database (CBM, Chinese),
China National Knowledge Infrastructure (CNKI, Chinese),
and Wangfang Database (Chinese). The association between
the MTHFR polymorphism and breast cancer risk was
conducted using odds ratios (ORs) and 95 % confidence
intervals (95 % CIs). Finally, a total of 22 studies with 6,103
cases and 7,913 controls were included in our meta-analysis:
13 studies with 3,273 cases and 4,419 controls for C677T
polymorphism and 9 studies with 2,830 cases and 3,494
controls for A1298C polymorphism. With regard to C677T
polymorphism, significant association was found with breast
cancer risk under three models (T vs. C: OR=1.12, 95 % CI=
1.02–1.23, P=0.015; TT vs. CC: OR=1.35, 95 % CI=1.10–
1.67, P=0.005; TT vs. CC/CT: OR=1.37, 95 % CI=1.11–
1.70, P=0.004). There was no significant association found
between A1298C polymorphism and breast cancer risk under
all genetic models (C vs. A: OR=0.96, 95 % CI=0.89–1.03,
P=0.268; CC vs. AA: OR=0.98, 95 % CI=0.77–1.26, P=
0.899; AC vs. AA: OR=0.95, 95 % CI=0.88–1.02, P=0.174;
CC vs. AC/AA: OR=1.00, 95 % CI=0.78–1.28, P=0.996,
CC/AC vs. AA: OR=0.96, 95 % CI=0.89–1.02, P=0.196).
In summary, during this meta-analysis, we found thatMTHFR
C677T polymorphismwas significantly associatedwith breast
cancer risk in the Chinese population. Meanwhile, MTHFR
A1298C polymorphism was not associated with breast cancer
risk in the Chinese population.
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Introduction
Breast cancer is one of the most prevalent invasive cancers and
the second leading global cause of cancer-related deaths among
women, in both developed and developing countries, which has
become a major public health challenge [1, 2]. Global breast
cancer incidence has been increasing by more than one million
new cases every year; the incidence is significantly higher in
developed countries than in developing countries [3]. Breast
cancer increased significantly in China, especially in Beijing
and Shanghai; it increased by 23 and 31 % within 10 years,
respectively. It is close to the levels of western high-prevalence
countries of breast cancer [4]. The mechanism of breast carcino-
genesis is still not fully understood. Some factors such as familial
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history of the disease, age of menarche and menopause, diet,
reproductive history, high estrogen exposure, and genetic factors
are considered to be risk factors for breast cancer. There are
studies suggesting that the effect determined by low-penetrance
genes may provide a plausible explanation for breast cancer
susceptibility, and in recent years, several common low-
penetrance genes have been identified as potential breast cancer
susceptibility genes [5–9].
As one of the important low-penetrance genes, 5,10-meth-
ylenetetrahydrofolate reductase (MTHFR ) encodes a critical
enzyme for intracellular folate homeostasis and metabolism,
which catalyzes the conversion of 5,10-methylenetetrahydro-
folate (5,10-methylene-THF) to 5-methyltetrahydrofolate (5-
methylene-THF), and it is thought to influence DNA methyl-
ation and nucleic acid synthesis [10–12]. The MTHFR poly-
morphisms were considered to be associated with breast can-
cer susceptibility [13, 14].
The C677T (rs1801133, Ala222Val) and A1298C
(rs1801131, Glu429Ala) are two common polymorphisms of
MTHFR genes. C677T is in exon 4 at nucleotide 677, which is
associated with the decrease of MTHFR activity and in-
creased the level of homocysteine and altered the distribu-
tion of folate, while A1298C (rs1801131, Glu429Ala) is
in exon 7 at nucleotide 1298, which is also related to the
reduction of MTHFR activity but at a lower degree com-
pared to C677T [15–17]. A number of studies indicate that
C677T and A1298C polymorphisms in the MTHFR gene
were involved in the etiology of breast cancer among the
Chinese population [18–31]. However, the results from
those studies remain conflicting.
In order to get more accurate results, we performed a meta-
analysis. In this study, we intend to explore the possible
association between two common variants of the MTHFR
gene, C677T and A1298C, and breast cancer risk in Chinese
patients. To our knowledge, this is the most comprehensive
meta-analysis conducted to date with respect to the association
betweenMTHFR gene polymorphisms and breast cancer risk
among the Chinese population.
Materials and methods
Search strategy
A comprehensive search strategy was conducted towards the
electronic databases including Medline, PubMed, Web of
Science, Embase, Chinese Biomedical Literature Database
(CBM, Chinese), China National Knowledge Infrastructure
(CNKI, Chinese), and Wangfang Database (Chinese) with
keywords “breast cancer,” “breast neoplasm,” “methylenetet-
rahydrofolate reductase,” “MTHFR ,” “polymorphism,” and
“variant” for all studies searched on the Chinese people, and
there were no limitations to the language of publications.
Additional studies were identified by a hand search of the
references of original studies; review articles were also exam-
ined to find additional eligible studies.
Inclusion and exclusion criteria
Eligible studies had tomeet all of the following criteria: (a) the
publication was a case–control study referring to the associa-
tion between MTHFR polymorphisms and breast cancer in
Chinese people; (b) the articles must offer the sample size,
distribution of alleles, genotypes, or other information for
estimating the odds ratio (OR) and 95 % confidence inter-
val (CI); (c) when multiple publications reported on the
same or overlapping data, we used the most recent or
largest population; and (d) the studies were published.
The following exclusion criteria were used for excluding
studies: (a) not a case–control study, (b) studies that contained
duplicate data, (c) no usable data reported, and (d) case reports
or reviews.
Data extraction
Data were carefully extracted by two authors independently
from each study based on the inclusion criteria mentioned
above. If conflicting evaluations were encountered, an agree-
ment was reached following a discussion; if agreement could
not be reached, then a third author was consulted to resolve the
debate. The following information were extracted: (a) the
name of the first author, (b) year of publication, (c) city
of origin, (d) the language of each study, (e) genotyping
methods, (f) source of the control group, and (g) distribu-
tion of genotypes in case and control groups. We also evalu-
ated whether the genotype distributions were in Hardy–
Weinberg equilibrium.
Statistical analysis
The strength of association between the MTHFR C677T poly-
morphisms and breast cancer riskwas evaluated byORand 95%
CI according to allele contrast (T vs. C), homozygote (TT vs.
CC), heterozygote (TC vs. CC), recessive (TT vs. TC/ CC), and
dominant (TT/TC vs. CC) models, while the possible association
between theMTHFR A1298C polymorphism and breast cancer
risk was assessed byOR and 95%CI according to allele contrast
(C vs. A), homozygote (CC vs. AA), heterozygote (CAvs. AA),
dominant (CC/AC vs. AA), and recessive (CC vs. AC/AA)
models, respectively. The heterogeneity was assessed by a chi-
square-based Q statistic test. The effect of heterogeneity was
quantified by using the I2 value as well as P value [32]. If the I2
value >50 % or P<0.10, then that suggests that obvious hetero-
geneity existed. ORswere pooled by a random effects model (the
DerSimonian and Laird method) [33]. Otherwise, a fixed effects
model (the Mantel–Haenszel method) was used [34].
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The Hardy–Weinberg equilibrium [35] of controls was
tested by using a professional web-based program (http://
ihg2.helmholtz-muenchen.de/cgibin/hw/hwa1.pl). If P >0.
05, then it suggests that the controls followed the Hardy–
Weinberg equilibrium (HWE) balance. Sensitivity analysis
was performed to assess the stability of the results. A single
study involved in the meta-analysis was removed each time to
reflect the influence of the individual data set to the pooled
ORs [36]. When the Hardy–Weinberg equilibrium disequilib-
rium existed (P <0.05 was considered statistically significant),
the sensitivity analysis was also conducted. Possible publica-
tion bias was assessed by Egger's test (P <0.05 was consid-
ered representative of statistically significant publication bias)
[37] and visual observation of funnel plot [38]. All statistical
tests were performed with STATA software (version 9.2, Stata
Corp.). A P value of less than 0.05 for any test or model was
considered to be statistically significant.
Results
Search results and study characteristics
After careful examination according to the inclusion criteria, a
total of 22 studies [18–31] with 6,103 cases and 7,913 controls
were included in our meta-analysis: 13 studies with 3,273 cases
and 4419 controls for C677T polymorphism (Table 1) and 9
studies with 2,830 cases and 3,494 controls for A1298C poly-
morphism (Table 2). The genotype distributions in the controls of
all studies were consistent with HWE (all P>0.05).
Meta-analysis results
Themain results of this meta-analysis and the heterogeneity test
were shown in Tables 3 and 4. With regard to C677T polymor-
phism, significant association was found with breast cancer risk
under three models (T vs. C: OR=1.12, 95 % CI=1.02–1.23,
P =0.015; TT vs. CC: OR=1.35, 95 % CI=1.10–1.67,
P =0.005 (Fig. 2a); TT vs. CC/CT: OR=1.37, 95 %
CI=1.11–1.70, P=0.004 (Fig. 2c)). In the heterozygote model
(TC vs. CC: OR=1.01, 95 % CI=0.96–1.06, P=0.659) and
dominant model (TT/TC vs. CC: OR=1.06, 95 % CI=0.99–
1.1, P=0.087 (Fig. 2b), no association was found between
C677T polymorphism and breast cancer risk. There was no
significant association found between A1298C polymorphism
and breast cancer risk under all genetic models (C vs. A:
OR=0.96, 95 % CI=0.89–1.03, P =0.268; CC vs. AA:
OR=0.98, 95 % CI=0.77–1.26, P =0.899; AC vs. AA:
OR=0.95, 95 % CI=0.88–1.02, P=0.174; CC vs. AC/AA:
OR=1.00, 95 % CI=0.78–1.28, P=0.996 (Fig. 1a); CC/AC
vs. AA: OR=0.96, 95 % CI=0.89–1.02, P=0.196).
Sensitivity analysis
Sensitivity analyses were conducted to determine whether
modification of the inclusion criteria of the meta-analysis
affected the final results. The statistical significance of the
results was not altered when any single study was omitted,
confirming the stability of the results (data not shown). So,
results of the sensitivity analyses suggest that the data in our
meta-analysis are relatively stable and credible.
Table 1 Characteristics of case–control studies included in MTHFR C667T (rs1801133, Ala222Val) polymorphism and breast cancer risk
First author Year City Language Genotyping methods Source of control Cases Controls
CC CT TT CC CT TT
Wu 2012 Yunnan English PCR-RFLP HB 32 30 13 37 32 6
Gao 2009 Nanjing English PCR-RFLP PB 217 327 125 257 329 96
Chou 2006 Taiwan English PCR-RFLP HB 73 51 18 132 120 33
Shrubsole 2004 Shanghai English PCR-RFLP PB 374 555 183 387 577 196
Inoue 2008 Singaporea English PCR-RFLP PB 239 120 21 393 226 43
Yu 2007 Taiwan English PCR-RFLP PB 56 44 9 225 170 25
Lin 2004 Taiwan English PCR-RFLP PB 43 38 7 173 145 24
Wu 2010 Heilongjiang Chinese PCR-RFLP HB 16 35 29 32 35 13
Yuan 2009 Heilongjiang Chinese PCR-RFLP PB 16 35 29 32 35 13
Hua 2011 Yunnan Chinese PCR-RFLP PB 65 21 9 52 27 11
Kan 2007 Yunnan Chinese PCR-RFLP PB 74 29 22 65 29 9
Li 2009 Guangdong Chinese PCR-RFLP PB 38 17 10 90 50 3
Qi 2004 Beijing Chinese PCR-RFLP PB 42 104 71 59 105 54
PCR-RFLP PCR-restriction fragment length polymorphism, HB hospital-based, PB population-based
a Singapore's Chinese people
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Publication bias
Funnel plot and Egger's test were performed to assess the
publication bias. Funnel plot is relatively straightforward to
observe whether the publication bias is present, and Egger's
test was used to provide statistical evidence of symmetries of
the plots. As shown in Fig. 1b (C677T polymorphism) and
Fig. 2d (A1298C polymorphism), the shape of the funnel plot
did not show obvious asymmetry. Similarly, the results of
Egger's test show that no publication bias was found too (all
P >0.05, data not shown).
Discussion
Breast cancer is one of the most common malignant tumors
and leading causes of cancer-related death among females in
the world, and it is a threat to women's health. In China,
incidence showed a clear upward trend, especially in urban
areas. Breast cancer incidence and mortality accounted for the
top three most common female malignancy in China. Many
candidate genes have been reported to be involved in breast
cancer susceptibility, including MTHFR , CYP19 [39],
CASP8 [40], GSM1 [7], hOGG1 [41], and so on. MTHFR
is one of the primary candidate genes concerning the alteration
of MTHFR enzyme activity which may influence the general
balance between DNA synthesis, repair, and methylation pro-
cesses [15, 16, 42]. A series of studies have investigated the
association between the MTHFR polymorphisms and breast
cancer susceptibility in the Chinese people, but got controver-
sial or inconclusive results.
Meta-analysis is a powerful tool for analyzing cumulative
data of studies wherein the individual sample sizes are small
and the disease can be easily masked by other genetic and
environmental factors [43, 44]. A meta-analysis potentially
investigates a large number of individuals and can estimate the
effect of a genetic factor on the risk of the disease [2]. The
present meta-analysis, including 22 studies with 6,103 cases
and 7,913 controls, explored the association between the
MTHFR C677T and A1298C polymorphisms and breast can-
cer risk. Our results indicate that the MTHFR A1298C poly-
morphism is not associated with breast cancer development in
Table 2 Characteristics of case–control studies included in MTHFR A1298C (rs1801131, Glu429Ala) polymorphisms and breast cancer risk
First author Year City Language Genotyping methods Source of control Cases Controls
AA AC CC AA AC CC
Wu 2012 Yunnan English PCR-RFLP HB 37 32 6 42 28 5
Gao 2009 Nanjing English PCR-RFLP PB 478 181 10 465 205 12
Chou 2006 Taiwan English PCR-RFLP HB 104 30 8 172 95 18
Shrubsole 2004 Shanghai English PCR-RFLP PB 768 311 42 824 344 40
Inoue 2008 Singaporea English PCR-RFLP PB 225 139 16 387 234 41
Hua 2011 Yunnan Chinese PCR-RFLP PB 50 42 3 55 32 3
Kan 2007 Yunnan Chinese PCR-RFLP PB 70 41 14 61 32 8
Lin 2010 Guangdong Chinese PCR-RFLP PB 45 14 6 98 35 10
Qi 2004 Beijing Chinese PCR-RFLP PB 155 58 4 144 71 3
PCR-RFLP PCR-restriction fragment length polymorphism, HB hospital-based, PB population-based
a Singapore's Chinese people
Table 3 Results of meta-analysis for MTHFR C667T (rs1801133,
Ala222Val) polymorphism and breast cancer risk
Comparison Test of association Mode Test of heterogeneity
OR 95 % CI P P I2 (%)
T vs. C 1.12 1.02–1.23 0.015 R 0 69.0
TT vs. CC 1.35 1.10–1.67 0.005 R 0.001 64.5
TC vs. CC 1.01 0.96–1.06 0.659 F 0.275 16.7
TT vs. TC/CC 1.37 1.11–1.70 0.004 R 0.003 59.3
TT/TC vs. CC 1.06 0.99–1.13 0.087 R 0.024 48.9
OR odds ratio, CI confidence interval, F fixed effects model, R random
effects model
Table 4 Results of meta-analysis for MTHFR A1298C (rs1801131,
Glu429Ala) polymorphism and breast cancer risk
Comparison Test of association Mode Test of heterogeneity
OR 95 % CI P P I2 (%)
C vs. A 0.96 0.89–1.03 0.268 F 0.303 15.6
CC vs. AA 0.98 0.77–1.26 0.899 F 0.857 0
AC vs. AA 0.95 0.88–1.02 0.174 F 0.200 27.4
CC vs. AC/AA 1.00 0.78–1.28 0.996 F 0.892 0
CC/AC vs. AA 0.96 0.89–1.02 0.196 F 0.211 26.2
OR odds ratio, CI confidence interval, F fixed effects model, R random
effects model
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Fig. 2 a The forest plot describing the meta-analysis under the homozygous
model for the association between MTHFR C677T polymorphism and the
risk of breast cancer in the Chinese population (TT vs. CC). b The forest plot
describing the meta-analysis under the dominance model for the association
betweenMTHFR C677T polymorphism and the risk of breast cancer in the
Chinese population (TT/TC vs. CC). c The forest plot describing the meta-
analysis under the recessive model for the association between MTHFR
C677T polymorphism and the risk of breast cancer in the Chinese population
(TT vs. TC/CC). d Begg funnel plot for publication bias test for the associ-
ation between MTHFR C677T polymorphism and the risk of breast cancer
under the heterozygous model (TC vs. CC). Each point represents a separate
study for the indicated association. Log [OR], natural logarithm of OR.
Horizontal line means effect size
Fig. 1 a The forest plot describing the meta-analysis under the recessive
model for the association betweenMTHFR A1298C polymorphism and the
risk of breast cancer in the Chinese population (CC vs. CA+AA). b Begg
funnel plot for publication bias test for the association between MTHFR
A1298C polymorphism and the risk of breast cancer under the recessive
model (CC vs. CA/AA). Each point represents a separate study for the
indicated association. Log [OR], natural logarithm of OR. Horizontal line
means effect size
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the Chinese population, but a strong association between
MTHFR C677T polymorphism and breast cancer risk was
found, indicating that potentially functional MTHFR C677T
polymorphism may play a low-penetrance role in the devel-
opment of breast cancer.
Although comprehensive analysis was conducted to show
the association between MTHFR polymorphism and risk of
breast cancer, there are still some limitations that should be
acknowledged. Firstly, the number of studies and the number of
samples included in the meta-analysis were relatively small.
Secondly, the controls were not uniformly defined. Some stud-
ies used controls that were population-based, while others used
hospital-based controls, which may not be representative of the
general population. Thirdly, our results were based on
unadjusted estimates, while a more precise analysis should be
conducted if individual data were available, which would allow
for the adjustment by other co-variants including age, meno-
pausal status, obesity, environmental factors, and lifestyle.
Despite the limitations above, our meta-analysis also had
several advantages: First, a meta-analysis of the association
between MTHFR polymorphism and breast cancer risk is
statistically more powerful than any other single study.
Second, a strict search strategy which combined computer-
assisted search and manual search makes the eligible studies
to be included as much as possible. Third, the quality of case–
control studies included in the meta-analysis met our inclusion
criteria and was satisfactory, and the sensitivity analysis and
publication bias analysis indicated that the results of our meta-
analysis are stable, credible, and convincing.
Conclusion
In summary, during this meta-analysis, we found that the
MTHFR C677T polymorphism was significantly associated
with breast cancer risk in the Chinese population. Meanwhile,
the MTHFR A1298C polymorphism was not associated with
breast cancer risk in the Chinese population. Considering the
limited sample size and ethnicities included in the meta-analysis,
further large-scale and well-designed studies are needed to con-
firm our results. Moreover, gene–gene and gene–environment
interactions should also be considered in a future analysis.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
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